These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 26118447)

  • 1. suPAR: A New Biomarker for Cardiovascular Disease?
    Hodges GW; Bang CN; Wachtell K; Eugen-Olsen J; Jeppesen JL
    Can J Cardiol; 2015 Oct; 31(10):1293-302. PubMed ID: 26118447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble urokinase plasminogen activation receptor--An emerging new biomarker of cardiovascular disease and critical illness.
    Cyrille NB; Villablanca PA; Ramakrishna H
    Ann Card Anaesth; 2016; 19(2):214-6. PubMed ID: 27052059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble urokinase plasminogen activator receptor is associated with subclinical organ damage and cardiovascular events.
    Sehestedt T; Lyngbæk S; Eugen-Olsen J; Jeppesen J; Andersen O; Hansen TW; Linneberg A; Jørgensen T; Haugaard SB; Olsen MH
    Atherosclerosis; 2011 May; 216(1):237-43. PubMed ID: 21354571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular risk prediction in the general population with use of suPAR, CRP, and Framingham Risk Score.
    Lyngbæk S; Marott JL; Sehestedt T; Hansen TW; Olsen MH; Andersen O; Linneberg A; Haugaard SB; Eugen-Olsen J; Hansen PR; Jeppesen J
    Int J Cardiol; 2013 Sep; 167(6):2904-11. PubMed ID: 22909410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble urokinase plasminogen activator receptor in plasma is associated with incidence of CVD. Results from the Malmö Diet and Cancer Study.
    Persson M; Engström G; Björkbacka H; Hedblad B
    Atherosclerosis; 2012 Feb; 220(2):502-5. PubMed ID: 22119508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of suPAR and hs-CRP on cardiovascular disease.
    Diederichsen MZ; Diederichsen SZ; Mickley H; Steffensen FH; Lambrechtsen J; Sand NPR; Christensen KL; Olsen MH; Diederichsen A; Grønhøj MH
    Atherosclerosis; 2018 Apr; 271():245-251. PubMed ID: 29402404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CRP and suPAR are differently related to anthropometry and subclinical organ damage.
    Lyngbæk S; Sehestedt T; Marott JL; Hansen TW; Olsen MH; Andersen O; Linneberg A; Madsbad S; Haugaard SB; Eugen-Olsen J; Jeppesen J
    Int J Cardiol; 2013 Aug; 167(3):781-5. PubMed ID: 22459389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population.
    Eugen-Olsen J; Andersen O; Linneberg A; Ladelund S; Hansen TW; Langkilde A; Petersen J; Pielak T; Møller LN; Jeppesen J; Lyngbaek S; Fenger M; Olsen MH; Hildebrandt PR; Borch-Johnsen K; Jørgensen T; Haugaard SB
    J Intern Med; 2010 Sep; 268(3):296-308. PubMed ID: 20561148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus.
    Enocsson H; Wetterö J; Skogh T; Sjöwall C
    Transl Res; 2013 Nov; 162(5):287-96. PubMed ID: 23916811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma soluble urokinase-type plasminogen activator receptor level is independently associated with coronary microvascular function in patients with non-obstructive coronary artery disease.
    Mekonnen G; Corban MT; Hung OY; Eshtehardi P; Eapen DJ; Al-Kassem H; Rasoul-Arzrumly E; Gogas BD; McDaniel MC; Pielak T; Thorball CW; Sperling L; Quyyumi AA; Samady H
    Atherosclerosis; 2015 Mar; 239(1):55-60. PubMed ID: 25574858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble urokinase plasminogen activator receptor as a prognostic marker of all-cause and cardiovascular mortality in a black population.
    Botha S; Fourie CMT; Schutte R; Eugen-Olsen J; Pretorius R; Schutte AE
    Int J Cardiol; 2015 Apr; 184():631-636. PubMed ID: 25771228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SuPAR, an emerging biomarker in kidney and inflammatory diseases.
    Hamie L; Daoud G; Nemer G; Nammour T; El Chediak A; Uthman IW; Kibbi AG; Eid A; Kurban M
    Postgrad Med J; 2018 Sep; 94(1115):517-524. PubMed ID: 30177549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble urokinase plasminogen activator receptor--a valuable biomarker in systemic lupus erythematosus?
    Enocsson H; Sjöwall C; Wetterö J
    Clin Chim Acta; 2015 Apr; 444():234-41. PubMed ID: 25704300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble Urokinase Plasminogen Activator Receptor (suPAR) as a Biomarker of Systemic Chronic Inflammation.
    Rasmussen LJH; Petersen JEV; Eugen-Olsen J
    Front Immunol; 2021; 12():780641. PubMed ID: 34925360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cadmium exposure is associated with soluble urokinase plasminogen activator receptor, a circulating marker of inflammation and future cardiovascular disease.
    Fagerberg B; Borné Y; Barregard L; Sallsten G; Forsgard N; Hedblad B; Persson M; Engström G
    Environ Res; 2017 Jan; 152():185-191. PubMed ID: 27792942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness of soluble urokinase plasminogen activator receptor (suPAR) as an inflammatory biomarker in obese children.
    Kosecik M; Dervisoglu P; Koroglu M; Isguven P; Elmas B; Demiray T; Altindis M
    Int J Cardiol; 2017 Feb; 228():158-161. PubMed ID: 27865178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble urokinase receptor is a biomarker of cardiovascular disease in chronic kidney disease.
    Meijers B; Poesen R; Claes K; Dietrich R; Bammens B; Sprangers B; Naesens M; Storr M; Kuypers D; Evenepoel P
    Kidney Int; 2015 Jan; 87(1):210-6. PubMed ID: 24897037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble urokinase-type plasminogen activator receptor (suPAR) as new biomarker of the prosthetic joint infection: correlation with inflammatory cytokines.
    Galliera E; Drago L; Marazzi MG; Romanò C; Vassena C; Corsi Romanelli MM
    Clin Chim Acta; 2015 Feb; 441():23-8. PubMed ID: 25499119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis.
    Zimmermann HW; Koch A; Seidler S; Trautwein C; Tacke F
    Liver Int; 2012 Mar; 32(3):500-9. PubMed ID: 22098627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble urokinase plasminogen activator receptor (suPAR) levels in healthy pregnancy and preeclampsia.
    Toldi G; Bíró E; Szalay B; Stenczer B; Molvarec A; Rigó J; Vásárhelyi B; Bekõ G
    Clin Chem Lab Med; 2011 Nov; 49(11):1873-6. PubMed ID: 21722073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.